Experts debate value of HER2 testing methods.
Nelson
N J
NJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015152:Blotting, Northern; D015139:Blotting, Southern; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000737:chemistry* / Q000188:drug therapy*; D004273:DNA, Neoplasm / Q000032:analysis; D017277:Drug Approval; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016133:Polymerase Chain Reaction; D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000187:drug effects / Q000235:genetics / Q000276:immunology; D000068878:Trastuzumab; D014481:United States; D014486:United States Food and Drug Administration; D015854:Up-Regulation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D011933:Reagent Kits, Diagnostic; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab